Abstract: The present invention provides methods for the removal, destruction or inactivation of intact nucleic acids contaminating desired biomolecules by the use of small molecule nucleic acid cleavage agents.

Abstract: Amplification mixtures, kits, amplicons, kits and processes are provided for amplifying a nucleic acid. In particular, provided are processes which utilize an amplification mixture comprising a polymerase, a deoxynucleotidetriphosphate (dNTP) mixture which contains modified dNTPs, a first primer and a second primer. Further provided are dNTP mixtures which contain modified dNTPs for at least two of the four nucleotide triphosphates, which when incorporated into a polynucelotide, impart resistance to enzymatic degradation by an exonuclease at the sites of incorporation of the modified dNTPs. Also provided are the amplicons and vectors which incorporate the modified nucleotides.

Abstract: The present invention is a flexible ocular restraint band that includes a thin flexible material such as a surgical mesh fabric with flexible reinforced end portions. The device is positioned posterior to the eye globe and the reinforced ends are sutured to anterior portions of the scleral ring. Preferably, a side edge of the band is formed with a concave curved edge to be placed proximate the optical nerve without making contact or applying pressure to the optical nerve. When properly positioned the device prevents further axial elongation of the eye. In alternative embodiments the band may be formed as a generally linear strap, a three legged or “Y” shaped strap or a four legged “X” shaped strap.

Abstract: The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Chagas disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as infected with Chagas disease or non-infected. The biomarkers can be detected by SELDI mass spectrometry.

Abstract: Amplification mixtures, kits, amplicons, kits and processes are provided for amplifying a nucleic acid. In particular, provided are processes which utilize an amplification mixture comprising a polymerase, a deoxynucleotidetriphosphate (DNTP) mixture which contains modified dNTPs, a first primer and a second primer. Further provided are DNTP mixtures which contain modified dNTPs for at least two of the four nucleotide triphosphates, which when incorporated into a polynucelotide, impart resistance to enzymatic degradation by an exonuclease at the sites of incorporation of the modified dNTPs. Also provided are the amplicons and vectors which incorporate the modified nucleotides.

Abstract: The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.

Abstract: Compositions and methods for making and using therapeutic formulations of measles virus antigens with a Proteosome-based adjuvant are provided. The measles virus antigens may be derived from a variety of sources, such as from recombinant production or from a split antigen preparation. The measles vaccine formulations may be used, for example, in methods for treating or preventing a measles virus infection and eliciting a protective immune response.

Abstract: A composition suitable for formulation of an enzymatic reaction mixture, the composition comprising a reaction component essential for an ex-vivo non-polymerase enzymatic reaction in which a substrate is catalyzed by an enzyme in a reaction mixture to form a product, and a tracer compatible with the enzyme, the composition being substantially free of the substrate.

Abstract: A composition suitable for formulation of an enzymatic reaction mixture, the composition comprising a reaction component essential for an ex-vivo non-polymerase enzymatic reaction in which a substrate is catalyzed by an enzyme in a reaction mixture to form a product, and a tracer compatible with the enzyme, the composition being substantially free of the substrate.

Abstract: A composition suitable for formulation of an enzymatic reaction mixture, the composition comprising a reaction component essential for an ex-vivo non-polymerase enzymatic reaction in which a substrate is catalyzed by an enzyme in a reaction mixture to form a product, and a tracer compatible with the enzyme, the composition being substantially free of the substrate.

Abstract: The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.

Abstract: Amplification mixtures, kits, amplicons, kits and processes are provided for amplifying a nucleic acid. In particular, provided are processes which utilize an amplification mixture comprising a polymerase, a deoxynucleotidetriphosphate (dNTP) mixture which contains modified dNTPs, a first primer and a second primer. Further provided are dNTP mixtures which contain modified dNTPs for at least two of the four nucleotide triphosphates, which when incorporated into a polynucelotide, impart resistance to enzymatic degradation by an exonuclease at the sites of incorporation of the modified dNTPs. Also provided are the amplicons and vectors which incorporate the modified nucleotides.

Abstract: Systems and methods are provided for aerosolizing a pharmaceutical formulation. According to one method, respiratory gases are prevented from flowing to the lungs when attempting to inhale. Then, respiratory gases are abruptly permitted to flow to the lungs. The flow of respiratory gases may then be used to extract a pharmaceutical formulation from a receptacle and to place the pharmaceutical formulation within the flow of respiratory gases to form an aerosol.

Abstract: The present invention is a flexible ocular restraint band that includes a thin flexible material such as a surgical mesh fabric with flexible reinforced end portions. The device is positioned posterior to the eye globe and the reinforced ends are sutured to anterior portions of the scleral ring. Preferably, a side edge of the band is formed with a concave curved edge to be placed proximate the optical nerve without making contact or applying pressure to the optical nerve. When properly positioned the device prevents further axial elongation of the eye. In alternative embodiments the band may be formed as a generally linear strap, a three legged or “Y” shaped strap or a four legged “X” shaped strap.

Abstract: A control system for individually controlling power from a single voltage source to a plurality of motors is described. A chopper circuit, in conjunction with the control system, generates drive-pulses, which operates the IGBT switching devices to sequentially provide pulses to each motor.

Abstract: A control system for individually controlling power from a single voltage source to a plurality of motors is described. A chopper circuit, in conjunction with the control system, generates drive-pulses, which operates the IGBT switching devices to sequentially provide pulses to each motor.

Abstract: Amplification mixtures, kits, amplicons, kits and processes are provided for amplifying a nucleic acid. In particular, provided are processes which utilize an amplification mixture comprising a polymerase, a deoxynucleotidetriphosphate (dNTP) mixture which contains modified dNTPs, a first primer and a second primer. Further provided are dNTP mixtures which contain modified dNTPs for at least two of the four nucleotide triphosphates, which when incorporated into a polynucelotide, impart resistance to enzymatic degradation by an exonuclease at the sites of incorporation of the modified dNTPs. Also provided are the amplicons and vectors which incorporate the modified nucleotides.

Abstract: Memory management to support calls between objects in language environments support automatic garbage collection and language environments requiring explicit control of object destruction is provided. Reference counting is used to automatically control the lifetime of objects requiring explicit destruction and that are to be accessible across the language boundary. A data structure is maintained in a runtime component for each object that is accessed over a language boundary. The reference count for each non-garbage collected object is incremented by the runtime in accordance with the number of cross-language references held to it. When the count reaches zero through decrements as the references are returned and destroyed, the non-garbage collected object can be safely and automatically destroyed. The runtime creates a strong reference to any garbage collected object accessed by a cross-language call.

Abstract: The invention provides a technique for generating minimal debugging type information in a distinguished compile unit while still supporting the debugging of classes for which the distinguished compile unit is not, in this module, being built or debugged, where the debugging information for the classes has been previously compiled into one or more object modules. On detecting a reference to a type in a program, the compiler inserts code into the module it is compiling to direct the linker where to locate the debugging information object module describing that type. Usually, the object module will be located in a separate link library, so the compiler directs the linker to add the debug library to the list of libraries from which it tries to resolve symbolic references, and to add a reference to an external linkage symbol defined in the object module describing the type. The linker will have to resolve this symbol by adding the debug library into the link.